NYSE:NVRO - Nevro Stock Price, Forecast & News

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) announced its quarterly earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.85) by $0.27. The medical equipment provider earned $100.16 million during the quarter, compared to analyst estimates of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The firm's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.37) EPS. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Nevro.

Nevro will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Nevro updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.4-114.4 million, compared to the consensus revenue estimate of $109.73 million.

12 analysts have issued 12-month target prices for Nevro's stock. Their forecasts range from $65.00 to $150.00. On average, they expect Nevro's stock price to reach $103.83 in the next twelve months. This suggests that the stock has a possible downside of 23.4%. View Analyst Price Targets for Nevro.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

Media headlines about NVRO stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Nevro.

Nevro saw a decrease in short interest in January. As of January 31st, there was short interest totalling 2,610,000 shares, a decrease of 9.1% from the January 15th total of 2,870,000 shares. Based on an average daily volume of 443,000 shares, the short-interest ratio is presently 5.9 days. Currently, 8.8% of the shares of the company are short sold. View Nevro's Current Options Chain.

Some companies that are related to Nevro include Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), NuVasive (NUVA), Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS) and Merit Medical Systems (MMSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Incyte (INCY), Micron Technology (MU), Starbucks (SBUX), ABIOMED (ABMD), Celgene (CELG) and Intercept Pharmaceuticals (ICPT).

Nevro's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (6.17%), Franklin Resources Inc. (4.30%), Jackson Square Partners LLC (3.91%), Perceptive Advisors LLC (2.46%), State Street Corp (2.29%) and Lord Abbett & CO. LLC (1.92%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Jackson Square Partners LLC, Perceptive Advisors LLC, Point72 Asset Management L.P., Franklin Resources Inc., Barclays PLC, Spark Investment Management LLC and Lord Abbett & CO. LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Renaissance Technologies LLC, Partner Fund Management L.P., AXA, Man Group plc, Geode Capital Management LLC and State of New Jersey Common Pension Fund D. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $135.49.

Nevro has a market capitalization of $4.20 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

The official website for Nevro is http://www.nevro.com/.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]